Efectos adversos cutáneos inmunorelacionados¿predictores de respuesta terapéutica de los inhibidores del punto de control inmunitario?

  1. Elena Lucía Pinto Pulido
  2. Miriam Fernández Parrado
  3. Francisco José Rodríguez Cuadrado
Revista:
MPG Journal

ISSN: 2171-9020

Any de publicació: 2023

Volum: 4

Número: 61

Tipus: Article

DIALNET GOOGLE SCHOLAR lock_openAccés obert editor

Altres publicacions en: MPG Journal

Resum

The introduction of immune checkpoint inhibitors has revolutionized cancer treatment in recent years. We comment on a multicenter retrospective cohort study comparing the survival of oncology patients treated with these drugs who developed immune-related skin adverse effects with those who did not.

Referències bibliogràfiques

  • Apalla Z, Nikolaou V, Fattore D, et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement. J Eur Acad Dermatol Venereol. 2022; 36(3):332-350. doi: 10.1111/jdv.17855.
  • Tang K, Seo J, Tiu BC, et al. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatol. 2022; 158(2):189-193. doi: 10.1001/jamadermatol.2021.5476.
  • Zhang S, Tang K, Wan G, et al. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study. J Am Acad Dermatol. 2023; 88(5):1024-1032. doi: 10.1016/j.jaad.2022.12.048.
Fuente de los datos: Dialnet